Marie Mc Carthy, ICON plc Dublin, Ireland,
J Prev Alzheimers Dis. 2019;6(4):217-220. doi: 10.14283/jpad.2019.32.
The report explores the potential digital technology has to generate novel endpoints and digital biomarkers for Alzheimer's disease drug development studies. Drawing from literature and novel pilots, we explore the value of innovative digital technology to digitize physiological behaviours such as sleep disturbance and gait changes. Technology now exists to monitor and quantify our use and interaction with electronics in the home, the use of social platforms and smart-phones, geolocation, sleep and activity patterns. These multimodal digital data are a feasible alternative to capturing the more complex activities of daily living that require higher cognitive processes and are a sensitive predictor of disease. The combination of biosensors and the internet of things (IoT), offers the potential to collect highly relevant, objective data in a continuous, passive and low burden manner. Digital endpoints and biomarkers could have value in the diagnosis, monitoring and development of therapies for patients living with Alzheimer's disease.
报告探讨了数字技术在阿尔茨海默病药物开发研究中产生新的终点和数字生物标志物的潜力。我们从文献和新的试点研究中探索了创新数字技术的价值，以数字化睡眠障碍和步态变化等生理行为。现在已经存在技术来监测和量化我们在家中使用和与电子设备的交互、使用社交平台和智能手机、地理位置、睡眠和活动模式。这些多模态数字数据是捕捉更复杂的日常生活活动的可行替代方案，这些活动需要更高的认知过程，并且是疾病的敏感预测指标。生物传感器和物联网 (IoT) 的结合提供了以连续、被动和低负担的方式收集高度相关、客观数据的潜力。数字终点和生物标志物在诊断、监测和治疗阿尔茨海默病患者方面可能具有价值。
